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A B S T R A C T
The aim of this study was to determine whether deletion 22q11.2 studies should become a part of a standardized diag-
nostic workup for selected groups of at risk patients. We prospectively investigated four cohorts of unselected patients re-
ferred because of: 1) congenital heart defect (CHD), 2) palatal anomalies, 3) hypocalcaemia, 4) dysmorphic features sug-
gestive of del 22q11.2. Fluorescence in situ hybridization analysis revealed deletion 22q11.2 in 9.4% (6/64) patients with
CHD. From 18 patients referred because of the hypocalcaemia, six (33.3%) had 22q11.2 deletion. In the group of 31 chil-
dren with dysmorphic traits, the diagnosis was confirmed in two (6.4%) patients. None of the 58 children with palatal
anomalies showed evidence of 22q11.2 deletion. Conclusions: Testing for the 22q11.2 microdeletion can be recommended
in all patients with conotruncal heart defects and in patients with hypocalcaemia. It should be also considered in pa-
tients presenting only with dysmorphic traits suggestive of del 22q11.2, while screening in patients with cleft palate is
not warranted.
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Introduction
Deletion 22q11.2 is the most common microdeletion
syndrome, usually presenting with combination of fea-
tures including cardiac defect, palatal abnormalities, cra-
niofacial dysmorphism and developmental delay. Due to
the variability of clinical expression, individuals with
mild clinical presentation can pass unobserved1. Early di-
agnosis is important for appropriate medical attention
including monitoring for complications and possibly for
predicting surgical outcome2,3. It also gives the opportu-
nity for timely genetic counselling and further testing in-
cluding prenatal diagnosis in familial cases. A possible
strategy for early identification of affected individuals is
routine screening for 22q11.2 deletion in all infants pre-
senting with one of the major clinical manifestations of
the disorder. The purpose of this study was to evaluate
the effectiveness of this approach by testing for del
22q11.2 unselected groups of patients with: heart defect,
cleft palate, hypocalcaemia and dysmorphic traits sug-
gestive of the del 22q11.2 phenotype (usually associated
with developmental or behavioural problems and occa-
sionally minor anomalies). To the best of our knowledge,
this is the first study dealing with the screening for dele-
tion 22q11.2 that covers all major clinical manifestations
of the syndrome.
Patients and Methods
We screened 171 patients within a time interval of
four years (from January 2001 to December 2004). There
were 64 patients with congenital heart defects (CHD), 58
patients with palatal anomalies, 18 patients with hypo-
calcaemia and 31 patients with dysmorphic traits sugges-
tive of del 22q11.2. All patients were evaluated by a clini-
cal geneticist (I.B.). Based on her findings, the first three
groups were divided into dysmorphic (at least three
dysmorphic features from the del 22q11.2 phenotype)
and non-dysmorphic subgroups. We also divided the pa-
tients with congenital heart defects according to the type
of malformation into two groups for further analysis.
Group I included 49 children with non-conotruncal heart
defects, and group II 15 patients with conotruncal heart
defects (CTD).
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Blood samples were taken after informed parental
consent was obtained. In each patient we performed
high-resolution chromosome analysis from phytohae-
magglutinin stimulated lymphocyte cultures by standard
methods. Fluorescence in situ hybridization (FISH) was
performed with commercially available DNA probe mix-
ture the LSI DiGeorge/VCFS region two-colour probe
(Vysis, Downers Growe, IL, USA) according manufac-
turer’s recommendations.
Results
A total of 171 patients were studied. There were 79
boys and 92 girls. The mean age was 5 years and 5
months (range from 4 days to 17 years and 10 months).
Clinical evaluation classified 112 patients as dysmorphic,
while 59 patients were classified as non-dysmorphic.
FISH analysis revealed 22q11.2 deletion in 14 cases
out of 171 investigated patients (8.2%). There were 9 fe-
males and 5 males, aged from 17 days to 11 years and 2
months. All identified patients with 22q11.2 deletion be-
longed to the dysmorphic subgroup (Table 1). The fre-
quency of the deletion among dysmorphic patients was
12.5% (14/112).
In the group of patients with congenital heart defects,
deletion 22q11.2 was found in 9.4% of patients (6/64).
The prevalence of deletion in the dysmorphic CHD pa-
tients was 15.4% (6/39). Table 2 provides a list of the
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TABLE 1
CLINICAL FINDINGS IN PATIENTS WITH 22q11.2 DELETION





1 2 3 4 5 6 7 8 9 10 11 12 13 14 14
Cardiac defect + + + + + + – – – – – – – – 6
Partial immunodeficiency – – – – + – – + – + + – – + 5
Hypocalcaemia – – – – – – + + + + + + – – 6




– + – – – + – – – + + + + + 7
Minor anomalies – + + – + – – + – – + – + – 6
Dysmorphic features + + + + + + + + + + + + + + 14
Growth retardation – – – + – – + + – – – + + – 5
Mental retardation – + – – – – – – – + + + – – 4
Other – + – – – – + – – + – – – – 3
CHD – congenital heart defect, CP – cleft palate, CLP – cleft lip and plate
TABLE 2
CHROMOSOME AND FISH STUDIES IN THE GROUP OF PATIENTS WITH NON-CONOTRUNCAL HEART DEFECTS
Patients
Dysmorphic Non-dysmorphic
CHD No 22q11.2 Other No 22q11.2 Other
ASD 15 11 – Opitz-Frias sy 4 – –
PDA 5 3 – – 2 – –
CoA 4 2 – 45,X 2 – –
PS/PA 4 3 1 – 1 – –
AVSD 3 2 – – 1 – –
AS 3 2 – – 1 – –
ASD, PS, AS 1 1 – 7q11.2 – – –
ASD, VSD 2 – – – 2 – –
VSD 12 5 1 – 7 – –
Total 49 29 2 3 20 – –
AS – aortic stenosis, ASD – atrial septal defect, AVSD – atrioventricular septal defect, CHD – congenital heart defect,
CoA – coarctation of the aorta, PDA – patent ductus arteriosus, PS – pulmonary stenosis, VSD – ventricular septal defect
non-conotruncal heart defects in the patients investi-
gated and the results of chromosome and FISH studies.
Microdeletion 22q11.2 was found in two patients, one
with pulmonary stenosis (PS), and one with ventricular
septal defect (VSD) (2/49 or 4.1%). In addition, we identi-
fied one patient with Turner syndrome and one patient
with Williams syndrome. One patient with atrial septal
defect (ASD) was clinically diagnosed as having Opitz
Frias syndrome, but FISH analysis for the TUPLE1 lo-
cus in this patient did not reveal 22q11.2 deletion. Table
3 summarizes findings in 15 patients who had conotrun-
cal heart defect. Among them the prevalence of 22q11.2
deletion was 26.6% (4/15). All four patients with micro-
deletion had tetralogy of Fallot (ToF).
None of the 58 patients with palatal anomalies (28
with cleft palate and 30 with cleft lip and plate) showed
evidence of 22q11.2 deletion. In the dysmorphic sub-
group of 27 patients, chromosome analysis of one female
patient with cleft lip/palate and dysmorphic traits re-
vealed r(18)(p11.2q23) karyotype.
In the group of patients with hypocalcaemia, deletion
22q11.2 was discovered in 6 of 18 patients (33.3%). Con-
sidering just the dysmorphic subgroup, microdeletion
was present in 40% (6/15) of patients.
In the group of 31 children with dysmorphic traits
from the del 22q11.2 phenotype spectrum, the deletion
was discovered in two (6.4%) patients. One patient with
short stature, and facial features suggestive of velocar-
diofacial syndrome (VCFS) including short palpebral fis-
sures, ptosis, high arched palate, and velopharingeal in-
sufficiency was diagnosed as being mosaic for Turner
syndrome (45,X/46,XX).
Discussion
We have prospectively investigated four unselected
cohorts of patients presenting with: 1) heart defect, 2)
cleft palate, 3) hypocalcaemia and 4) dysmorphic fea-
tures suggestive of del 22q11.2. The objective of the
study was to determine should 22q11.2 deletion studies
become a part of a standardized diagnostic workup for
the subset of patients presenting with the major clinical
manifestations of the del 22q11.2 spectrum.
A total of 14 patients were found to have a 22q11.2 de-
letion, all without visible cytogenetic abnormalities. The-
re were six patients with congenital heart defects, six pa-
tients with hypocalcaemia and two patients with dysmor-
phic traits.
Congenital heart disease is a highly characteristic fea-
ture of del 22q11.2 syndrome, occurring in about 75–88%
of all patients4,5. Several studies have reported preva-
lence of 22q11.2 microdeletion in unselected CHD pa-
tients6–10. Large variations in prevalence rates (from 1.5
to 43.5 %) are mainly due to the sample differences (se-
lection of CHD studied, age of patients, presence of
dysmorphic traits, and/or other extracardiac symptoms,
etc). The high frequency of 43.5% found by Johnson et
al.9 is probably due to the study design, because he inves-
tigated a selected group of patients that were referred to
a cytogenetic laboratory for evaluation. The prevalence
rate of 1.5% found in the population-based study by
Botto et al.7 most likely reflects the true prevalence in
the newborn population. In our patients with CHD,
FISH analysis revealed 22q11.2 deletion in 9.4% (one pa-
tient with PS, one with VSD and four patients with ToF).
In the dysmorphic group the prevalence was 15.4%. Our
results are in accordance with the findings of a similarly
designed study by Fokusten et al.8 who found del 22q11.2
in 8% of patients with unselected CHD and 17.6% in the
subset of patients with extracardiac symptoms.
About 14–18% of patients with del 22q11.2 have the
perimembranous type of VSD5,11,12. We found one patient
with deletion among 12 patients presenting with VSD
(8.3%). In a cohort of 125 patients with VSD McEhinney
et al.13 found the deletion in 10% of cases.
It is now well established that conotruncal heart de-
fects are the most typical cardiac malformations associ-
ated with the 22q11.2 deletion4,5. In our study 26.6% pa-
tients with CTD carried the deletion. The incidence of
22q11.2 deletion in patients with CTD in other studies
shows a wide range from 0% up to 48%14–19. Here again
the different rates are due to the study design. Debrus et
al.14 investigated only non-syndromic familial cases of
CTD and found no deletion. High rates are found in stud-
ies that investigated only the newborn population or se-
lected CTDs known to be associated more often with del
22q11.217,19,20.
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TABLE 3
CHROMOSOME AND FISH STUDIES IN THE GROUP OF PATIENTS WITH CONOTRUNCAL HEART DEFECTS
Patients
Dysmorphic Non-dysmorphic
CTD No 22q11.2 Other No 22q11.2 Other
TGA 3 2 – – 1 – –
ToF 9 7 4 – 2 – –
IAA 2 1 – – 1 – –
DAA 1 – – – 1 – –
Total 15 10 4 – 5 – –
CTD – conotruncal heart defect, DAA – double aortic arch, IAA – interrupted aortic arch, ToF – tetralogy of Fallot, TGA – transposi-
tion of the great arteries
Given the high frequency of del 22q11.2 in patients
with CTD, some authors have suggested that all patients
with CTD should undergo screening for the deletion21,22.
Other authors advocate screening only in patients with
additional extracardiac symptoms6,8. Four patients with
del 22q11.2 and CTD in our sample were found among 10
patients in the dysmorphic subgroup. Still, most of the
clinical features were quite mild and could pass unob-
served if not specifically looked for by an experienced cli-
nician. Exceptionally mild dysmorphic features were seen
in a girl with pulmonary stenosis. She had hooded eye-
lids, proturberant ears, and slight micrognathia, but her
facial appearance was otherwise normal. There were no
hypocalcaemia, or clinical signs of impaired immunity, al-
though subsequent laboratory investigation revealed mild
partial depression of cellular immunity. Her somatic and
intellectual development was normal. Recent study of
adult CTD patients found that clinical evaluation inaccu-
rately predict microdeletion in some FISH negative pa-
tients and incorrectly predicted absence of the deletion in
some FISH positive patients. In half (3/6) of the detected
patients with del 22q11.2 typical dysmorphic features
were absent23. In view of the high frequency of del
22q11.2 among CTD patients, the fact that clinical diag-
nosis is unreliable, and the fact that patients go undiag-
nosed into adulthood, we think that screening for 22q11.2
should be considered in all CTD patients.
Palatal anomalies including velopharyngeal incompe-
tence or submucosal cleft are often found in del 22q11.2,
but overt cleft palate or cleft lip/palate is found only in
2–11% of patients4,5,24. In our group of 58 patients with
oral clefts no deletion of 22q11.2 region was detected in-
dicating that among these patients deletion rarely oc-
curs. Other studies also suggest that deletion 22q11.2 is
rarely found among patients with oral clefts25,26. Ruiter
et al.27 found one patient with del 22q11.2 out of 58 chil-
dren with isolated cleft palate. A larger study comprising
101 patients with isolated cleft palate found only three
patients (2.8%) with the deletion28.
It is remarkable to note that of 18 unselected patients
referred because of hypocalcaemia, six had 22q11.2 dele-
tion. The age at diagnosis ranged from 2 months to 11
years and two months. The older age of diagnosis in four
of our patients indicates that the risk of hypocalcaemic
episodes is often present beyond the neonatal period. All
patients were referred for evaluation because of convul-
sions. None of them had a heart defect or cleft palate.
Two had sensorineural hearing loss, and three had par-
tial immunodeficiency with no evident clinical manifes-
tations. Of four older patients that could be formally
tested, three showed mild to borderline mental retarda-
tion. One female patient had mild dysmorphic features,
and no additional findings from the del 221q11.2 pheno-
type. Her intellectual development was normal. Hypopa-
rathyroidism and facial dysmorphism have occasionally
been described as the only sign of the del 22q11.2 syndro-
me29,30. High incidence of 22q11.2 deletion in patients
with hypocalcaemia (neonatal, transient, latent, perma-
nent or late-onset) was also noted by the some other
authors4,31,32. Although based on a small sample of pa-
tients, our results indicate that individuals presenting
with hypocalcaemia with no obvious reason, should be
also tested for 22q11.2 deletion.
In the group of 31 patients with dysmorphic features
of 22q11.2 microdeletion syndrome we discovered two
patients with 22q11.2 deletion. The age at diagnosis was
3 years and four months and 4 years and three months
respectively. Both patients had mild developmental delay.
Although dysmorphic features were present in all pa-
tients discovered in our series, they were often mild and
could easily be overlooked if not evaluated by an experi-
enced clinical geneticist. Further studies of the group of
patients presenting with dysmorphic features, minor un-
specific anomalies and/or developmental delay by molec-
ular methods would be of interest because some of them
could have atypical deletions in the 22q11.2 region33.
To summarise, although the number of investigated
patients in our study was not large, we think that the de-
scribed findings can well support our view that it is ap-
propriate to evaluate for 22q11.2 deletion syndrome pa-
tients with apparently isolated conotruncal caridac de-
fects and patients presenting with hypocalcaemia. As
dysmorphic features could be the only presenting sing of
del 22q11.2, we also advocate testing for del 22q11.2 in
this group of patients. Del 22q11.2 is rarely detected in
patients with cleft palate and screening of this group of
patients is not warranted.
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PROBIR DEL 22q11 U RIZI^NIM SKUPINAMA BOLESNIKA
S A @ E T A K
Cilj ovog rada je utvrditi da li analiza delecije 22q11.2 treba postati dio rutinskog dijagnosti~kog ispitivanja kod
selekcioniranih skupina rizi~nih bolesnika. Prospektivno smo ispitali 4 skupine neselekcioniranih bolesnika upu}enih
zbog 1) kongenitalne sr~ane mane, 2) anomalije nepca, 3) hipokalcemije, 4) dizmorfi~nih obilje`ja 22q11.2 delecije.
Metodom fluorescentne in situ hibridizacije otkrivena je delecija 22q11.2 kod 9,4% (6/64) bolesnika sa sr~anom manom.
Od 18 bolesnika s hipokacemijom {est (33,3%) je imalo 22q11.2 deleciju. U skupini od 31 djeteta s dismorfijom dijagnoza
je potvr|ena kod dva (6,4%) bolesnika. Kod nijednog od 58 djece s anomalijama nepca nije utvr|ena 22q11.2 delecija.
Analizu mikrodelecije 22q11.2 preporu~a se napraviti kod svih bolesnika s konotrunkalnom sr~anom manom i boles-
nika s hipokalcemijom. Tako|er bi trebalo uzeti u obzir i bolesnike kod kojih su prisutna samo dismorfi~na obilje`ja
delecije 22q11.2, dok probir kod bolesnika s rascjepom nije opravdan.
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